secwatch.observer — SEC 8-K summary
======================================

Issuer:     REGENERON PHARMACEUTICALS, INC. (REGN)
CIK:        0000872589
Form:       8-K
Filed at:   2023-09-08T23:59:59+00:00
Accession:  0001104659-23-099345
Event type: leadership
Sentiment:  neutral
Materiality: 0.65
Item codes: 5.02
LLM model:  deepseek-v4-flash:cloud@v2

Regeneron CFO Landry to retire Feb 2024; Fenimore named successor; two new directors elected
--------------------------------------------------------------------------------

- Director Marc Tessier-Lavigne retired Sept 1, 2023 due to potential conflicts with other roles.
- CFO Robert E. Landry to retire in Feb 2024; Christopher Fenimore (SVP, Controller) to succeed him.
- Board elected Kathryn Guarini as Class III director and David Schenkein as Class II director effective Sept 8, 2023.
- Both new directors appointed to Audit (Guarini) and Technology (Schenkein) committees.
- No disagreements cited for Landry departure; new directors hold office until 2024 annual meeting.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/872589/000110465923099345/0001104659-23-099345-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/872589/000110465923099345/tm2325712d2_8k.htm
  HTML page:      https://secwatch.observer/filing/0001104659-23-099345

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer